Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

PDMR Shareholding

15 Aug 2019 16:59

RNS Number : 2441J
Mereo BioPharma Group plc
15 August 2019
Β 

Mereo BioPharma Group plc

Β 

Β ("Mereo" or the "Company")

Β 

Notification of PDMR Dealing

Β 

London, August 15, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on August 13, 2019, Charles Sermon, General Counsel, purchased 590 American Depositary Shares (ADSs) at a price of USD3.09 per ADS. On August 14, 2019, Charles purchased 754 ADSs at a price of USD3.11 per ADS.

Β 

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

Β 

1

Details of the person discharging managerial responsibilities

Β 

a)

Name

Charles Sermon

Β 

2

Reason for the notification

a)

Position/status

General Counsel

Β 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

Β 

b)

LEI

213800U8JQHIJOS5AS09

Β 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

Β 

b)

Nature of the transaction

PURCHASE OF ADS

c)

Price(s) and volume(s)

Β 

Price(s)

Volume(s)

USD 3.09

590

Β 

Β 

d)

Aggregated information: volume, Price

Aggregated volume: 590

Aggregated price: USD3.087

e)

Date of the transaction

2019-08-13

f)

Place of the transaction

XNMS

Β 

Β 

1

Details of the person discharging managerial responsibilities

Β 

a)

Name

Charles Sermon

Β 

2

Reason for the notification

a)

Position/status

General Counsel

Β 

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

Β 

b)

LEI

213800U8JQHIJOS5AS09

Β 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES OF GBP0.003 EACH

Β 

b)

Nature of the transaction

PURCHASE of ADS

c)

Price(s) and volume(s)

Β 

Price(s)

Volume(s)

USD3.11

754

Β 

Β 

d)

Aggregated information: volume, Price

Aggregated volume: 754

Aggregated price: GBP3.105

e)

Date of the transaction

2019-08-14

f)

Place of the transaction

XNMS

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHBUGDIIUBBGCU
Date   Source Headline
15th Dec 20206:22 pmRNSAIM Delisting
30th Nov 20207:00 amRNSKey Dates for AIM Delisting
23rd Nov 202012:00 pmRNSMereo appoints Suba Krishnan
16th Nov 202012:00 pmRNSVirtual R&D Day
11th Nov 20207:00 amRNSCancellation of AIM admission
10th Nov 202012:00 pmRNSStifel 2020 Virtual Healthcare Conference
20th Oct 202012:00 pmRNSAppointments of CFO and SVP
19th Oct 202012:00 pmRNSTIGIT IND FDA Clearance
12th Oct 20201:44 pmRNSPDMR Notification
9th Oct 20204:05 pmRNSDirector/PDMR Shareholding
7th Oct 202012:00 pmRNSRegistration Statement Filed with US SEC
29th Sep 202012:00 pmRNSInterim Results for 6 months ended June 30, 2020
28th Sep 20203:21 pmRNSResult of General Meeting
28th Sep 202012:00 pmRNSChanges to Board of Directors
24th Sep 202012:00 pmRNSFDA Rare Pediatric Disease Designation
16th Sep 20201:00 pmRNSNotice of Interim Results
4th Sep 20207:00 amRNSNotice of General Meeting
25th Aug 202012:00 pmRNSInitiation of COVID-19 Respiratory Disease Trial
14th Aug 20207:00 amRNSPDMR Notification
13th Aug 20207:00 amRNSNotification of PDMR Dealing
6th Aug 20207:00 amRNSAppointment of Nominated Adviser & Broker
5th Aug 20207:00 amRNSDirector Dealing
6th Jul 20203:59 pmRNSHolding(s) in Company
6th Jul 20209:34 amRNSBlock Listing Application
30th Jun 20201:39 pmRNSResult of General Meeting
30th Jun 202012:00 pmRNSCSO and SVP appointments
29th Jun 20203:56 pmRNSResult of Annual General Meeting
22nd Jun 20204:33 pmRNSHolding(s) in Company
22nd Jun 202011:06 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSFinal Results for the year ended December 31, 2019
11th Jun 20204:41 pmRNSSecond Price Monitoring Extn
11th Jun 20204:36 pmRNSPrice Monitoring Extension
10th Jun 20205:30 pmRNSHolding(s) in Company
9th Jun 20204:45 pmRNSNotice of General Meeting
8th Jun 20205:56 pmRNSHolding(s) in Company
8th Jun 20205:18 pmRNSHolding(s) in Company
8th Jun 20203:20 pmRNSHolding(s) in Company
5th Jun 20203:55 pmRNSHolding(s) in Company
5th Jun 202012:49 pmRNSHolding(s) in Company
4th Jun 20202:05 pmRNSSecond Price Monitoring Extn
4th Jun 20202:00 pmRNSPrice Monitoring Extension
4th Jun 20207:00 amRNSCompletion of $70 Million Private Placement
3rd Jun 20209:05 amRNSSecond Price Monitoring Extn
3rd Jun 20209:00 amRNSPrice Monitoring Extension
27th May 202012:00 pmRNSNotice of Annual General Meeting
22nd May 202012:00 pmRNSAnnual General Meeting
21st May 20204:18 pmRNSHolding(s) in Company
27th Mar 202012:00 pmRNSBusiness Update and Directorate Change
6th Mar 20207:00 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.